REGENXBIO and Voyager Therapeutics Announce Exercise of Options for Rights to NAV Vectors
November 29, 2016 08:00 ET
|
REGENXBIO Inc.
ROCKVILLE, Md. and CAMBRIDGE, Mass., Nov. 29, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of...
REGENXBIO to Present at the 28th Annual Piper Jaffray Healthcare Conference
November 17, 2016 16:01 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Nov. 17, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
REGENXBIO Reports Third Quarter 2016 Financial Results and Recent Operational Highlights
November 09, 2016 16:05 ET
|
REGENXBIO Inc.
On track to dose first patient for Phase I/II clinical trial of RGX-501 for the treatment of homozygous familial hypercholesterolemia by the end of 2016Initiated manufacturing of material for Phase...
REGENXBIO to Host Conference Call on November 9 to Discuss Third Quarter 2016 Financial Results and Recent Operational Highlights
November 02, 2016 07:00 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Nov. 02, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
REGENXBIO to Present at the Jefferies Gene Editing and Gene Therapy Summit
October 04, 2016 16:15 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Oct. 04, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
REGENXBIO Publishes Data from Ongoing Preclinical Studies of NAV® Gene Therapy in Neurodegenerative Diseases
September 13, 2016 07:00 ET
|
REGENXBIO Inc.
Preclinical study of RGX-111 for the treatment of Mucopolysaccharidosis Type I (MPS I) demonstrates disease correction from a single administration of NAV AAV9 in a canine model; expected to help...
REGENXBIO to Participate in Global Healthcare Conferences
September 07, 2016 16:01 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Sept. 07, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
Daniel Tassé Appointed to REGENXBIO Board of Directors
August 16, 2016 08:00 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Aug. 16, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
REGENXBIO Reports Second Quarter 2016 Financial Results and Recent Operational Highlights
August 09, 2016 08:00 ET
|
REGENXBIO Inc.
On track to enroll first patients for Phase I/II clinical trial of RGX-501 for the treatment of homozygous familial hypercholesterolemia in the second half of 2016Received FDA Rare Pediatric Disease...
Daniel J. Abdun-Nabi Appointed to REGENXBIO Board of Directors
August 08, 2016 16:01 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Aug. 08, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...